Regeneron's (NASDAQ:REGN) stock has increased by 34% in 2020 as the company and its partner Sanofi (NASDAQ:SNY) initiated two large scale phase 2/3 clinical trials in March where it is providing an existing drug, Kevzara, to treat patients with severe COVID-19, the disease caused by the novel coronavirus. This development has investors optimistic about its prospects. But Regeneron's financial performance for the full year will be driven by the company's core business of treating eye diseases, asthma, eczema, and cancer.
Let's take a closer look at the biotech stock's main revenue drivers to decide if it's a buy today.
IMAGE SOURCE: GETTY IMAGES
As of April 9, there have been over 1.4 million worldwide confirmed COVID-19 cases and almost 90,000 virus-related deaths. While there are no approved drugs to effectively treat COVID-19 patients, many companies, including Regeneron, have commenced clinical trials to determine whether existing compounds used for other diseases can help these patients recover.
In March, Regeneron and Sanofi announced that they initiated two large phase 2/3 trials to assess whether Kevzara can prevent lung damage and respiratory distress in patients with severe COVID-19. Regeneron and Sanofi currently market Kevzara as a treatment for adult patients with rheumatoid arthritis (RA). Kevzara blocks the interleukin-6 (IL-6) protein, which may cause a patient's immune system to overreact and damage the lungs.
Recently, a preliminary study performed at a Munich Hospital found patients who have a minimal amount of IL-6 protein have significantly lower rates of respiratory failure and may not need mechanical ventilation. Earlier, a small Chinese study showed that patients who received Actemra, Roche Holdings' (OTC:RHHBY) IL-6 receptor antagonist and competing RA drug, were able to be discharged from the hospital and return home.
Eylea, an injectable drug that prevents blindness, grew by 14% in the U.S. to over $4.6 billion in 2019 (about 60% of Regeneron's sales). Eylea's revenues should continue to increase as it the company fully launches a pre-filled syringe delivery option for physicians and continues to market to the drug to adults with age-related macular degeneration (AMD), a disease that affects almost 11 million people in the U.S and is the leading cause of vision loss in Americans 60 and older. Eylea prevents the disease from progressing to an advanced stage and results in rapid, large sustained improvement for patients with mild to moderate AMD.
Regeneron will also benefit from growth in its diabetic eye business as it has established a dedicated salesforce to specifically contact specialists that see these types of patients. The company is devoting a significant amount of resources to improve on the low current rates of diagnosis and treatment of diabetic retinopathy (DR). DR is a complication of diabetes that causes damage to the retina and can lead to severe vision loss. Early treatment with Eylea, however, can halt the progress of DR, reducing the risk of blindness. This is a welcome development for the almost 8 million people who have DR.
Dupixent sales reported by Sanofi grew by almost 151% to over $2.3 billion in 2019 as physicians prescribed the drug to other adult patients with eczema and treated patients in three new sub-segments (asthma, children with eczema, and adults with chronic long-term sinus inflammation linked to nasal polyps). While Sanofi records all of global Dupixent sales on its income statement, it paid Regeneron over $1.4 billion in contribution revenue in 2019, up 40%, relating to royalties and profits from Dupixent (and two other drugs).
Dupixent should continue to grow as it is used for other patients in these three markets and it will enjoy further growth if it obtains approval from the Food and Drug Administration (FDA) for using the drug for asthma in pediatrics, chronic obstructive pulmonary disease, eczema in pediatrics, and several other indications.
Regeneron generated $176 million in revenue from Libatyo in 2019, up from almost $15 million in 2018. Libtayo treats advanced Cutaneous Squamous Cell Carcinoma (CSCC), a form of skin cancer that accounts for an estimated 7,000 deaths each year in the U.S. As of November 2019, its share of U.S. patients with CSCC was 43%, up from 3% when it was launched in October 2018.
Regeneron is currently testing Libtayo in Non-Small Cell Lung Cancer (NSCLC) patients, cervical cancer, and Basal Cell Carcinoma (BCC; the most common form of skin cancer). Libtayo's revenues should increase in the near-term as physicians continue to prescribe the drug for their CSCC patients and the drug is eventually used in other types of cancers.
I consider to be Regeneron a buy right now because it has ample opportunity to increase the revenue and profits it currently generates from its three key drugs, Eylea, Dupixent, and Libtayo. While investors will be waiting for further updates on Kevzara, they should focus and monitor Regeneron's progress in expanding its the diabetic eye segment, further penetrating the three emerging areas for Dupixent, gaining market share in CSCC, and obtaining FDA approval for treating other indications with these drugs.
While it's easy to be enthralled by its progress in the COVID-19 space, investors thinking about buying Regeneron would do well to consider the stock from a more holistic stance. And it looks good from here.
Originally posted here:
Here's Why Regeneron's Stock Is Worth More Than Its Coronavirus Work - Citybizlist Real Estate
- WHO launches new initiative to tackle the main cause of vision impairment - December 19th, 2024
- Blindness Advocates on Why There Should Be Audio Description Oscars - Variety - December 19th, 2024
- Diabetic retinopathy is treatable and preventable but only if you catch it in time - USA TODAY - December 19th, 2024
- AI: Could it help prevent blindness in diabetics? - BBC.com - December 19th, 2024
- Health Officials Investigate Rare Form of Blindness Tied to Ozempic - Gizmodo - December 19th, 2024
- Ozempic Could Be Blinding People Trying to Lose Weight - VICE - December 19th, 2024
- What is retinitis pigmentosathe vision disorder in the movie Blink? - National Geographic - December 19th, 2024
- VR shows promise in aiding navigation of people with blindness or low vision - Health Tech World - December 19th, 2024
- Ozempic could be linked to a common cause of sudden blindness, study finds - Quartz - December 19th, 2024
- New virtual realitytested system shows promise in aiding navigation of people with blindness or low vision - Tech Xplore - December 19th, 2024
- Ex-meth user who gouged her own eyeballs out while high says she is happier years after nightmarish episode - New York Post - December 19th, 2024
- Officials investigating link between Ozempic and eye-rotting disease that makes people blind - Daily Mail - December 19th, 2024
- Youngster to 'have eye removed' after minor fall - but NHS waitlist 'over 3 years' - NationalWorld - December 19th, 2024
- Restoring Vision: The Promise of Stem Cells in Healing Blindness - This is Local London - December 19th, 2024
- COAVS and Fred Hollows Foundation strengthen efforts to combat blindness in Pakistan - 24newshd - December 19th, 2024
- Study finds link between Ozempic and increased risk of vision loss - The Express Tribune - December 19th, 2024
- Going blind at 33 is devastating I wont see my childrens faces as they grow up - The Telegraph - December 19th, 2024
- Europol terror report reveals stark blindness about where the danger lies - Gript - December 19th, 2024
- Elton John lost his vision; signs and symptoms of eye infections that can cause blindness - The Times of India - December 6th, 2024
- Elton John's battle with blindness: How 77-year-old star's husband David Furnish guided him around premiere as - Daily Mail - December 6th, 2024
- Experimental study shows connection between COVID infection and age-related blindness - Medical Xpress - December 6th, 2024
- Elton John confirms shocking blindness after severe infection fight: I havent been able to see.. - Hindustan Times - December 6th, 2024
- Yes, an Eye Infection *Can* Lead To Vision Loss Heres How - Katie Couric Media - December 6th, 2024
- Elton John Battling Partial Blindness After Serious Eye Infection - Digital Music News - December 6th, 2024
- CU Anschutz researchers working to cure blindness through total eye transplantation - 9News.com KUSA - December 6th, 2024
- Elton John lost his vision from an eye infection. Here's why that might happenand how to prevent it - Fortune - December 6th, 2024
- Elton John announces blindness due to infection - CBS19.tv KYTX - December 6th, 2024
- David Frost: I suffer from face blindness. As a politician, being unable to identify people is agony - The Telegraph - December 6th, 2024
- Hes still standing how Elton John has survived far worse than blindness - The Telegraph - December 6th, 2024
- Foundation Fighting Blindness Partners with University of Colorado Anschutz Medical Campus and Other Leading Institutions to Secure Up to $46 Million... - December 6th, 2024
- Walmart helping low vison and blind customers shop with new app - KSLA - December 6th, 2024
- Elton John Says He Is Blind In The Right Eye Due to An Infection; What Is It All About? - Times Now - December 6th, 2024
- Trumps Win: The Blindness of Republicans and Democrats - The Times of Israel - December 6th, 2024
- Heres every song on The Agency soundtrack - NME - December 6th, 2024
- Elton John's worrying health battles in full as he confirms blindness - The Mirror - December 6th, 2024
- Symptoms of serious eye infections after Elton John says he is now blind - LADbible - December 6th, 2024
- Shocking! Elton John Reveals Blindness After Severe Eye Infection: Havent Been Able To... - Republic World - December 6th, 2024
- Face blindness will be examined as part of new project - BBC - December 6th, 2024
- Make your Word documents accessible to people with disabilities - November 27th, 2024
- Make your Word documents accessible to everyone with Accessibility ... - November 27th, 2024
- Use color and contrast for accessibility in Microsoft 365 - Microsoft ... - November 27th, 2024
- Accessibility tools for Word - Microsoft Support - November 27th, 2024
- Rules for the Accessibility Checker - Microsoft Support - November 27th, 2024
- Everything you need to know to write effective alt text - November 27th, 2024
- Create or edit a hyperlink - Microsoft Support - November 27th, 2024
- Video: Check the accessibility of your document - Microsoft Support - November 27th, 2024
- Woman lives with unique condition that means she can still see where things are despite being blind - LADbible - November 27th, 2024
- Arrogance and inherent blindness: Civil probe slams Netanyahu for Oct. 7 failures - The Times of Israel - November 27th, 2024
- Are pistachios the secret to preventing blindness as you age? - The Times of India - November 27th, 2024
- AI is helping people with blindness navigate the world around them - Spectrum News 1 - November 27th, 2024
- Unraveling the Mysteries of Cerebral/Cortical Visual Impairment | Newswise - Newswise - November 27th, 2024
- The silent struggles of color blind students in the UK - News-Medical.Net - November 27th, 2024
- An ideal way to treat Indias corneal blindness problem - The Hindu - November 27th, 2024
- Elle Fanning Has Blush Blindness (and She's Not Afraid to Say It!)This $13 Product Is Key - Who What Wear - November 27th, 2024
- This simple nut is the key to fighting age-related blindness - The Economic Times - November 27th, 2024
- Morning Open Thread: To Lose in Ignorant Blindness What We Might Hold Fast - Daily Kos - November 27th, 2024
- The Murder Capital confirm details of third album Blindness - DIY Magazine - November 27th, 2024
- World report on vision - World Health Organization (WHO) - November 16th, 2024
- Eye care, vision impairment and blindness programme - November 16th, 2024
- $45,000 Raised to benefit SGML Eye Hospital near Ujjain, India for rural and underserved population to prevent blindness - The Indian Panorama - November 16th, 2024
- Foundation Fighting Blindness Funds 35 New Research Grants in FY2024, Renames Key Program to Honor Former Board Chair - PR Newswire - November 16th, 2024
- Fighting blindness with Love Tags - WFLA - November 16th, 2024
- Woman With Rare Disease Waiting For Blindness To 'Cure' Hallucinations - News18 - November 16th, 2024
- Color Blindness Market Is Anticipated To Grow In A Promising - openPR - November 16th, 2024
- Towards a truer vision of broader inclusivity - The New Indian Express - November 16th, 2024
- WHO launches first World report on vision - October 22nd, 2024
- Eye health, vision impairment and blindness - World Health Organization ... - October 22nd, 2024
- Onchocerciasis - World Health Organization (WHO) - October 22nd, 2024
- Eye care, vision impairment and blindness: Refractive errors - October 22nd, 2024
- Blindness Prevention and Control - World Health Organization (WHO) - October 22nd, 2024
- Onchocerciasis (river blindness) - World Health Organization (WHO) - October 22nd, 2024
- Trachoma - World Health Organization (WHO) - October 22nd, 2024
- Blindness is not a curse to be broken - America: The Jesuit Review - October 22nd, 2024
- Alfred University gives away two pairs of EnChroma glasses for color blindness - www.alfred.edu - October 22nd, 2024
- All the Plants We Cannot See - The Revelator - October 22nd, 2024
- ASI Power Summit 2024: How Blindness Helped Michael Hingson Survive the 9/11 Attacks - ASI - October 22nd, 2024
- People with blindness and their allies rally outside Uber and Lyft over ride denials - The Mercury News - October 22nd, 2024
- New Study Links Ozempic to BlindnessBut They Can Actually Protect Your Eyes - First For Women - October 22nd, 2024
- Conservatives Use Trump Assassination Attempt to Target Women in Anti-Diversity War - The American Prospect - October 22nd, 2024
- Google AI to help detect preventable blindness in India and Thailand - Techloy - October 22nd, 2024